Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 34 of 46 for:    disulfiram

Disulfiram in Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02678975
Recruitment Status : Recruiting
First Posted : February 10, 2016
Last Update Posted : April 4, 2019
Sponsor:
Collaborators:
St. Olavs Hospital
Lund University Hospital
Karolinska University Hospital
University Hospital, Linkoeping
Region Örebro County
Ryhov County Hospital
Uppsala University Hospital
Information provided by (Responsible Party):
Asgeir S. Jakola, Sahlgrenska University Hospital, Sweden

Brief Summary:

Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism. There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent. The potency of disulfiram as an anticancer agent seems strengthened by copper.

The investigators aim is to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy.


Condition or disease Intervention/treatment Phase
Glioma Glioblastoma Drug: Disulfiram Dietary Supplement: Copper Drug: Alkylating Agents Phase 2 Phase 3

Detailed Description:

Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism. There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent. The potency of disulfiram as an anticancer agent seems strengthened by copper. There is now anecdotal clinical evidence of disulfiram as an anticancer agent. So far no clinical studies have been published in glioma patients, but two small, uncontrolled studies are planned according to clinicaltrials.gov. with search 1st November 2015.

The investigators aim to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy. The study will be performed as a multicenter RCT including patients in Norway and Sweden. This will serve as a proof-of concept study.

The primary end-point is survival at 6 months


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial
Study Start Date : January 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Disulfiram

Arm Intervention/treatment
Active Comparator: Control
Alkylating chemotherapy
Drug: Alkylating Agents
Alkylating antineoplastic agent
Other Name: lomustine (CCNU), PCV or temozolomide

Experimental: Experimental
Alkylating chemotherapy + disulfiram + copper
Drug: Disulfiram
Disulfiram 400 mg daily

Dietary Supplement: Copper
nutritional supplement with copper, 2 mg daily

Drug: Alkylating Agents
Alkylating antineoplastic agent
Other Name: lomustine (CCNU), PCV or temozolomide




Primary Outcome Measures :
  1. Survival 6 mo [ Time Frame: Proportion of alive participants at 6 months ]

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Proportion without progression at 6 and 12 months ]
    Using RANO criteria applied by local investigators

  2. Survival 12 and 24 mo [ Time Frame: Proportion of alive participants at 12 and 24 months ]
  3. Median overall survival [ Time Frame: Median overall survival assessed at 6 months and 24 months after last included participant ]
    Using Kaplan Meier plots and log-rank test

  4. Health related quality of life [ Time Frame: Assessed at baseline and month 3, 6, 9, 12, 15, 18, 21, 24 ]
    EuroQol 5D (generic)

  5. Volumetric tumor assessment [ Time Frame: Baseline and first follow-up scan being scheduled at 3 months post-inclusion ]
    Tumor volumes are assessed using semi-automatic segmentation

  6. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Assessed month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24, but analyzed as cumulative burden at 6 and 24 months ]
    Cumulative burden at 6 and 24 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A previous diagnosis of glioblastoma (histologically verified) and presenting with a first progression/recurrence documented by MRI.
  2. Indication for treatment with chemotherapeutic alkylating agents (i.e. temozolomide OR lomustine including PCV treatment).
  3. Age 18 years or older.
  4. Karnofsky performance status of 60 - 100 .
  5. Not receiving another experimental treatment for glioblastoma at the moment of inclusion or during active treatment within the assigned group (i.e. control or disulfiram group).
  6. Able to take oral medications.
  7. No known allergy to disulfiram or copper.
  8. Absolute neutrophil count ≥ 1,500/mcL and platelets ≥ 100,000/mcL
  9. Serum/plasma copper and serum ceruloplasmin within institutional limits.

    a. However increased levels are seen together with ongoing acute phase reaction as determined by elevated C-reactive protein (ceruloplasmin is elevated as part of the same process) it is possible to retest after normalization of C-reactive protein.

  10. Willing to refrain from ingestion of alcoholic beverages while on the study is a criteria to be randomized. However, once randomized alcohol abstinence only affects the group treated with disulfiram, and in this group it includes the entire period and one month after last dosage of disulfiram.

Exclusion Criteria:

  1. Earlier treatment for progression (e.g. "rescue therapy")
  2. History of idiopathic seizure disorder, psychosis or schizophrenia.
  3. History of uncontrolled hypertension (i.e. systolic BP > 180 mmHg) and a diagnosis of congestive heart failure
  4. Received radiotherapy within the 3 months before the diagnosis of progression .
  5. Addiction to alcohol or drugs.
  6. Pregnant and/or breastfeeding.
  7. Women of childbearing potential who do not have negative pregnancy test not older than 14 days before enrollment.
  8. History of active liver disease, including chronic active hepatitis, viral hepatitis (hepatitis B, C and CMV), cholestatic jaundice of any etiology or toxic hepatitis or inadequate hepatic function, defined as baseline ASAT and ALAT > 2.5 X upper institutional limit and/or bilirubin > 2.0 X upper institutional limit.
  9. History of Wilson's disease or family member with Wilson's disease (unless excluded as a carrier by genetic test).
  10. History of hemochromatosis or family member with hemochromatosis (unless excluded as a carrier by genetic test).
  11. Nickel hypersensitivity (disulfiram mobilize nickel causing a brief increase in nickel concentrations before excretion. The initial increase may lead to hepatitis and predisposed patients).
  12. Need for metronidazole, warfarin and/or theophylline medication (the metabolism may be influenced by disulfiram).
  13. Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives (phenytoin, phenobarbital, chlordiazepoxide, imipramine, diazepam, isoniazid, metronidazole, warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram).
  14. Unfit for participation for any other reason judged by the including physician.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02678975


Contacts
Layout table for location contacts
Contact: Asgeir S Jakola, MD, PhD asgeir.jakola@vgregion.se

Locations
Layout table for location information
Norway
Cancer Clinic, St.Olavs University Hospital Recruiting
Trondheim, Norway
Contact: Tora S Solheim, MD, PhD         
Principal Investigator: Tora S Solheim, MD, PhD         
Sweden
Dept. of Oncology, Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden
Contact: Katja Werlenius, MD         
Principal Investigator: Katja Werlenius, MD         
Ryhov County Hospital Recruiting
Jönköping, Sweden
Contact: Michael Strandéus, MD         
Principal Investigator: Michael Strandéus, MD         
Linköping University Hospital Recruiting
Linkoping, Sweden
Contact: Munila Mudaisi, MD         
Principal Investigator: Munila Mudaisi, MD         
Lund University Hospital Recruiting
Lund, Sweden
Contact: Sara Kinhult, MD, PhD         
Principal Investigator: Sara Kinhult, MD, PhD         
Karolinska University Hospital Recruiting
Stockholm, Sweden
Contact: Sofia Hylin, MD         
Principal Investigator: Sofia Hylin, MD         
Uppsala University Hospital Recruiting
Uppsala, Sweden
Contact: Magnus Lindskog, MD, PhD         
Principal Investigator: Magnus Lindskog, MD, PHD         
Örebro University Hospital Recruiting
Örebro, Sweden
Contact: David Löfgren, MD         
Principal Investigator: David Löfgren, MD         
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
St. Olavs Hospital
Lund University Hospital
Karolinska University Hospital
University Hospital, Linkoeping
Region Örebro County
Ryhov County Hospital
Uppsala University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Asgeir S Jakola, MD, PhD Sahlgrenska University Hospital, Sweden

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Asgeir S. Jakola, MD, PhD, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier: NCT02678975     History of Changes
Other Study ID Numbers: no ID yet
First Posted: February 10, 2016    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Disulfiram
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Copper
Temozolomide
Alkylating Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Trace Elements
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Alcohol Deterrents
Acetaldehyde Dehydrogenase Inhibitors
Enzyme Inhibitors